Newsletter
Sign up for the Fund's newsletter and get the lastest news, calls and events
| Titel Sort descending | Periode | Program | |
|---|---|---|---|
| NeuroPharm - Center for Experimental Medicine Neuropharmacology | 2015 - 2022 | Grand Solutions
|
|
|
NeuroPharm - Center for Experimental Medicine Neuropharmacology
Period
2015 - 2022
Region
Program
Grand Solutions Area
Biotek, Medico og Sundhed Investment
Percentage
35.38 Invested
15.6 mill. Budget
44.1 mill. Partners
Martinos Center, Imperial College London, Imanova, Rigshospitalet, University of Copenhagen, Glostrup Hospital People
Aktiv
Read more about the project
| |||
| Neuroprotective sortilin inhibition in glaucoma | 2023 - 2025 | Innobooster
|
|
|
Neuroprotective sortilin inhibition in glaucoma
Period
2023 - 2025
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
31.4 Invested
1.5 mill. Budget
4.7 mill. Partners
Vesper Biotechnology
(formerly Insusense) People
Read more about the project
| |||
| NeuroVision | 2020 - 2021 | Innobooster
|
|
|
NeuroVision
Period
2020 - 2021
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
1.0 mill. Budget
3.2 mill. Partners
Neurons Inc. People
NEURONS INC. ApS
Read more about the project
| |||
| Neutraliseringsenhed til fækalier | 2018 - 2019 | Innobooster
|
|
|
Neutraliseringsenhed til fækalier
Period
2018 - 2019
Region
Region Syddanmark Program
Innobooster Area
Ikke defineret Investment
Percentage
32.96 Invested
285.450 Budget
866.000 Partners
JVJ Maskinfabrik ApS People
JVJ MASKINTEKNIK ApS
Read more about the project
| |||
| Neutron focusing optics for neutron facilities | 2024 - 2026 | Innobooster
|
|
|
Neutron focusing optics for neutron facilities
Period
2024 - 2026
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
35 Invested
1.0 mill. Budget
2.9 mill. Partners
CHEXS People
Read more about the project
| |||
| Never Another ApS (under stiftelse) | 2023 - 2024 | Innofounder
|
|
|
Never Another ApS (under stiftelse)
Period
2023 - 2024
Region
Program
Innofounder Area
Ikke defineret Investment
Percentage
100 Invested
430.000 Budget
430.000 Never Another skaber made-to-measure, bøjlefrie bh’er med fokus på pasform og komfort. Vi anvender kundens egne mål og en digital produktionsprocess, for at skabe det bedste, personlige fit.
Egen data viser at:
- 66-70% oplever udfordringer med at finde bh med god pasform.
- 63-69% oplever udfordringer med størrelser i bøjlefri bh’er.
Kvinder går på kompromis med komfort eller pasform, og det giver en følelse af at være forkert ift. udbuddet.
Én respondent fortalte: ”Når man har stor omkreds og lille skål, er det nærmest umuligt at finde en bh. Det syntes jeg gør mig ubehagelig bevidst om min størrelse - Eller at jeg ”burde” have større bryster.”
Made-to-measure bh’er giver kunden en oplevelse af, at deres kropstype er genkendt og anerkendt, og at de får en bh med den bedste pasform, som ikke irriterer i løbet af dagen.
Never Another’s mission er, at få kvinder til at føle sig set og anerkendt, uanset størrelse og form. Kvinder fortjener undertøj som er behageligt, og som passer.
Udover at løse det konkrete problem, fokuserer vi på beklædningsindustriens generelle og enorme overproduktion af tøj.
Beklædningsindustrien producerer årligt 62 mio. ton tøj, og står for over 10% af verdens samlede Co2 udledning. Danskernes tøjforbrug ligger 35% højere end verdensgennemsnittet.
Ved først at producere produktet efter bestilling, undgår vi overproduktion og tekstil spild.
Partners
Never Another ApS People
Read more about the project
| |||
| New Acylation Technologies for Selective Protein and Peptide Modification | 2019 - 2022 | Industrial Researcher
|
|
|
New Acylation Technologies for Selective Protein and Peptide Modification
Period
2019 - 2022
Region
Region Hovedstaden Program
Erhvervsforsker Area
Biotek, Medico og Sundhed Investment
Percentage
50.1 Invested
1.1 mill. Budget
2.1 mill. Partners
Aarhus University, Novo Nordisk A/S People
Novo Nordisk A/S
Read more about the project
| |||
| New applications and test modalities for the Audible Contrast Threshold (ACT) test | 2021 - 2024 | Industrial Researcher
|
|
|
New applications and test modalities for the Audible Contrast Threshold (ACT) test
Period
2021 - 2024
Region
Region Hovedstaden Program
Erhvervsforsker Area
Ikke defineret Investment
Percentage
39.21 Invested
1.1 mill. Budget
2.7 mill. Partners
Technical University of Denmark, Interacoustics IRU People
Interacoustics IRU
Read more about the project
| |||
| New approach to correct Beta hemoglobinopathies using CRISPR-Cas12a | 2021 - 2021 | Innobooster
|
|
|
New approach to correct Beta hemoglobinopathies using CRISPR-Cas12a
Period
2021 - 2021
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
1.4 mill. Budget
4.3 mill. Partners
Twelve Bio ApS People
Twelve Bio ApS
Read more about the project
| |||
| New biologicals for carbon capture and storage | 2023 - 2025 | Global Research Collaborations
|
|
|
New biologicals for carbon capture and storage
Period
2023 - 2025
Region
Program
Global Research Collaborations Area
Ikke defineret Investment
Percentage
70 Invested
4.6 mill. Budget
6.6 mill. Partners
Bioomix ApS People
Read more about the project
| |||
| New digital platform for real-time registry and assessment of patient reported outcomes to improve the clinical support of urinary incontinence | 2019 - 2019 | Innobooster
|
|
|
New digital platform for real-time registry and assessment of patient reported outcomes to improve the clinical support of urinary incontinence
Period
2019 - 2019
Region
Region Midtjylland Program
Innobooster Area
Ikke defineret Investment
Percentage
31.48 Invested
167.223 Budget
531.250 Partners
Journl A / S People
Journl A/S
Read more about the project
| |||
| New drug for Treatment-Resistant Depression | 2020 - 2022 | Innobooster
|
|
|
New drug for Treatment-Resistant Depression
Period
2020 - 2022
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
4.2 mill. Budget
12.8 mill. Partners
Lophora Aps People
Lophora ApS
Read more about the project
| |||
| New drug for Treatment-Resistant Depression | 2022 - 2023 | Innobooster
|
|
|
New drug for Treatment-Resistant Depression
Period
2022 - 2023
Region
Program
Innobooster Area
Ikke defineret Investment
Percentage
29.2 Invested
708.218 Budget
2.4 mill. Partners
Lophora Aps People
Read more about the project
| |||
| New Drugs for Resistant Enterobactericeae | 2020 - 2021 | Innoexplorer
|
|
|
New Drugs for Resistant Enterobactericeae
Period
2020 - 2021
Region
Region Syddanmark Program
Innoexplorer Area
Bioressourcer, Fødevarer og Livsstil Investment
Percentage
100 Invested
1.5 mill. Budget
1.5 mill. Partners
Syddansk Universitet People
Syddansk Universitet
Read more about the project
| |||
| New Human Capital Management Portal | 2020 - 2020 | Innobooster
|
|
|
New Human Capital Management Portal
Period
2020 - 2020
Region
Region Hovedstaden Program
Innobooster Area
Ikke defineret Investment
Percentage
33 Invested
498.710 Budget
1.5 mill. Partners
CC-Interactive APS People
CC-INTERACTIVE ApS
Read more about the project
| |||